The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer
Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.
Authors
- Maria Joana Catarata (ORCID: https://orcid.org/0000-0001-8027-6979)
- Boris Duchemann (ORCID: https://orcid.org/0000-0003-0872-2983)
- M. Mayenga (ORCID: https://orcid.org/0000-0002-4748-2911)
- Thomas Gille (ORCID: https://orcid.org/0000-0002-1577-6595)
- Marion Ferreira (ORCID: https://orcid.org/0000-0001-6311-0256)
- Ana Rita Pedroso
Institutions
- Université de Tours (FR)
- Inserm (FR)
- Université Paris-Saclay (FR)
- Sorbonne Université (FR)
- Université Sorbonne Paris Nord (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Association pour la Recherche en Physiologie de l’Environnement (FR)
- Hôpitaux Universitaires Paris-Ouest (FR)
- Hôpital Avicenne (FR)
- Hospital Braga (PT)
- Hôpital Jean-Verdier (FR)
- Hôpital Foch (FR)
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto (PT)
- Clinical Academic Center of Braga (PT)
- Centre d'Étude des Pathologies Respiratoires (FR)
Publication Details
- Journal
- Breathe
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1183/20734735.0044-2024
- Citations
- 4
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.68